Similar articles

• Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.

  McCullough A. McCullough A. Curr Urol Rep. 2004 Dec;5(6):451-9. doi: 10.1007/s11934-004-0070-2. Curr Urol Rep. 2004. PMID: 15541215 Review.
• Phosphodiesterase 5 inhibitors in male sexual dysfunction.

  Kuthe A. Kuthe A. Curr Opin Urol. 2003 Sep;13(5):405-10. doi: 10.1097/00042307-200309000-00008. Curr Opin Urol. 2003. PMID: 12917517 Review.
• Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.

  Kloner RA. Kloner RA. Circulation. 2004 Nov 9;110(19):3149-55. doi: 10.1161/01.CIR.0000146906.42375.D3. Circulation. 2004. PMID: 15533876 Review. No abstract available.
• Tadalafil and vardenafil.

  Neumeyer K, Kirkpatrick P. Neumeyer K, et al. Nat Rev Drug Discov. 2004 Apr;3(4):295-6. doi: 10.1038/nrd1362. Nat Rev Drug Discov. 2004. PMID: 15124623 No abstract available.
• Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.

  Perimenis P. Perimenis P. Expert Opin Pharmacother. 2005 Jan;6(1):1-2. doi: 10.1517/14656566.6.1.1. Expert Opin Pharmacother. 2005. PMID: 15709877 No abstract available.